Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
71 pending office actions • 43 clients • 65 examiners • 28 art units • 0 of 71 (0%) have an AI response strategy ready
HOXIE & ASSOCIATES LLC specializes in the Biotechnology & Pharmaceuticals technology area. The firm has managed 2146 career applications, demonstrating a strong history of handling complex biological and chemical patent filings. Its resolved allowance rate pct of 82.49 indicates a high frequency of successful outcomes for its clients in this challenging field. This metric underscores the firm's proficiency in securing intellectual property in the life sciences sector.
Currently, the firm is managing 46 pending office actions, representing its ongoing workload before the patent office. The firm averages 3.79 avg office actions per allowance, reflecting the typical level of examiner interaction required to reach a grant. For practitioners, the 82.49 resolved allowance rate pct and 3.79 avg office actions per allowance serve as key metrics for evaluating the firm's prosecution strategy and efficiency across its 2146 career applications. These data points help set realistic expectations for the prosecution cycle in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (6%) |
| §103 only | 10 (14%) |
| §102 only | 1 (1%) |
| §112 only | 13 (18%) |
| Double-patenting only | 4 (6%) |
| Double-patenting + other | 21 (30%) |
| Multi-statute (no §101) | 17 (24%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.6% | +27.2% |
| COLEMAN, BRENDA LIBBY | 2 | 74.9% | +15.5% |
| PECKHAM, RICHARD GRANT | 2 | 68.1% | +35.1% |
| PUTTLITZ, KARL J | 2 | 69.1% | +18.6% |
| ARNOLD, ERNST V | 2 | 48.2% | +12.9% |
| SHOWALTER, ALEXANDER KEITH | 2 | 54.4% | +26.3% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| YU, HONG | 1 | 30.9% | +5.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18304987 | USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA | MEJIAS, SAMANTHA LEE | 88d overdue |
| 18548719 | Method of Evaluating the Biofilm Detachment Efficacy of Compositions | SWIFT, CANDICE LEE | 2d overdue |
| 18873307 | MINOXIDIL ADJUVANT THERAPIES | TRUONG, QUANGLONG N | — |
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | — |
| 18820161 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | AHVAZI, BIJAN | — |
| 18842265 | AZAPHILONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS | JACKSON, SHAWQUIA | — |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 17831796 | Oral Care Products and Methods | ARNOLD, ERNST V | 58d overdue |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | PECKHAM, RICHARD GRANT | 26d |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | COLEMAN, BRENDA LIBBY | 27d |
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | — |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | PALENIK, JEFFREY T | — |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1641 | 3 |
| 1614 | 3 |
| 1628 | 3 |
| 1658 | 3 |
| 1642 | 2 |
| 1615 | 2 |
| 1618 | 2 |
| 1624 | 2 |
| 1623 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 19540268 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §102Other | Final Rejection | — | Pending | Feb 13, 2026 |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | Apeiron Therapeutics (Hong Kong) Ltd. | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | Hutchmed Limited | HUYNH, PHUONG N | 1641 | §112 | Final Rejection | — | Pending | Oct 30, 2025 |
| 19274087 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | Novaliq GmbH | YU, HONG | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2025 |
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Levitasbio, Inc. | MARTIN, PAUL C | 1653 | §103§112DP | Non-Final OA | — | Pending | May 08, 2025 |
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | Shenzhen Oralead Pharma Co., Ltd. | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | — | Pending | Apr 30, 2025 |
| 18873307 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. | TRUONG, QUANGLONG N | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 | |
| 18869588 | TREATMENT OF CANCER WITH S1P RECEPTOR AGONISTS | Priothera Limited | COLEMAN, BRENDA LIBBY | §112 | Non-Final OA | — | Pending | Nov 26, 2024 | |
| 18868772 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | Idorsia Pharmaceuticals Ltd. | KOSACK, JOSEPH R | §112 | Non-Final OA | — | Pending | Nov 24, 2024 | |
| 18952990 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | Safety Shot, Inc. | MERCIER, MELISSA S | §112DP | Non-Final OA | — | Pending | Nov 19, 2024 | |
| 18867252 | IMPROVED SYNTHETIC METHODS FOR MAKING LACTONES | P2 Science, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | 18d overdue | Pending | Nov 19, 2024 |
| 18866978 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | KIFLE, BRUCK | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 | |
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | Genequantum Healthcare (Suzhou) Co., Ltd. | EVANS, JASMINE AFIYA | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 | |
| 18897877 | SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS | Novaliq GmbH | PECKHAM, RICHARD GRANT | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 | |
| 18847121 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 | |
| 18843308 | MODULATORS OF ACKR3 AND USES THEREOF | Stichting VU | SEAMAN, D MARGARET M | §112 | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18819236 | CRYSTALS | Aeromics, Inc. | COUGHLIN, MATTHEW P | §103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 | |
| 18820161 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | Osmo Labs, Pbc | AHVAZI, BIJAN | §102§112 | Non-Final OA | — | Pending | Aug 29, 2024 | |
| 18842265 | AZAPHILONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS | Ocean University Of China | JACKSON, SHAWQUIA | §102§112 | Non-Final OA | — | Pending | Aug 28, 2024 | |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | Alfasigma S.p.A. | KUCKLA, ANNA GRACE | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 | |
| 18784569 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | Novaliq GmbH | PALENIK, JEFFREY T | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18833346 | NOVEL COMPOSITIONS | Tulex Pharmaceuticals, Inc. | HOLLOMAN, NANNETTE | §103§112DP | Non-Final OA | — | Pending | Jul 25, 2024 | |
| 18777765 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | SHIAO, REI TSANG | DP | Non-Final OA | — | Pending | Jul 19, 2024 | |
| 18729674 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | Friedrich Miescher Institute For Biomedical Research | DHAR, MATASHA | §112 | Non-Final OA | — | Pending | Jul 17, 2024 | |
| 18755795 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited | WILLIS, DOUGLAS M | DPOther | Non-Final OA | — | Pending | Jun 27, 2024 | |
| 18741740 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. | O DELL, DAVID K | 1621 | §102§103DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18714302 | Rapid T-Cell Manufacturing | Kure Cells, Inc. | EBBINGHAUS, BRIANA NOEL | §102§103§112 | Non-Final OA | — | Pending | May 29, 2024 | |
| 18709201 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | BERRY, LAYLA D | §102§103§112 | Non-Final OA | — | Pending | May 10, 2024 | |
| 18705346 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd. | BAUER, BRIANNA LEE | §112 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18703113 | SILYL ETHER DERIVATIVES OF POLYETHER POLYMERS | P2 Science, Inc. | BAHTA, MEDHANIT W | §112 | Non-Final OA | — | Pending | Apr 19, 2024 | |
| 18693766 | FORMULATIONS AND USES OF RESVERATROL | Danstar Ferment AG | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18546831 | COMPOSITION FOR SKIN REGENERATION, WHITENING, ANTIOXIDATION, OR WOUND TREATMENT, COMPRISING STEM CELL-DERIVED EXOSOME AS ACTIVE INGREDIENT, AND USE THEREOF | Ehlbio Co., Ltd. | CLARK, AMY LYNN | 1628 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18690068 | GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD | Beijing Genecradle Pharmaceutical Co., Ltd. | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18580492 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | Alephoson Biopharmaceuticals Limited | COFFA, SERGIO | §103§112 | Non-Final OA | — | Pending | Jan 18, 2024 | |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 | |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. | PUTTLITZ, KARL J | §103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 | |
| 18390274 | PROCESS TO RECOVER AMMONIUM BICARBONATE FROM WASTEWATER | Bion Environmental Technologies, Inc. | RUMP, RICHARD M | 1759 | §101DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18564510 | ANTIBODY SPECIFICALLY BINDING TO ASM PROTEIN | Isu Abxis Co., Ltd. | PRIEST, JESSICA MARIE | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 27, 2023 | |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Montelino Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 27d | Pending | Nov 08, 2023 |
| 18481168 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | RODRIGUEZ-GARCIA, VALERIE | 1600 | §103DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18550088 | THE OXIDATION OF CARBON-HYDROGEN BONDS USING OZONE | P2 Science, Inc. | CUTLIFF, YATE KAI RENE | 1692 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18550087 | THE OXIDATION OF CARBON-HYDROGEN BONDS OF POLYMERS USING OZONE | P2 Science, Inc. | DARLING, DEVIN MITCHELL | 1764 | §102§103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18550111 | DETECTION OF BIOMARKERS USEFUL IN DIAGNOSING CHRONIC ENTEROPATHIES IN CATS | Vetica Labs, Inc. | ROONEY, NORA MAUREEN | 1641 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18464129 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | Team Medical, LLC | SHIN, DANA H | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Brightgene Bio-Medical Technology Co., Ltd. | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 14d | Pending | Sep 07, 2023 |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd. | CHO, DAVID H | 1693 | DP | Final Rejection | 9d | Pending | Sep 01, 2023 |
| 18548719 | Method of Evaluating the Biofilm Detachment Efficacy of Compositions | The Ohio State University | SWIFT, CANDICE LEE | 1657 | §101§103§112DP | Final Rejection | 2d overdue | Pending | Sep 01, 2023 |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | Idorsia Pharmaceuticals Ltd. | ROMERO, KRISTEN WANG | 1624 | §102§112DP | Non-Final OA | 87d overdue | Pending | Jul 27, 2023 |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | UNIVERSITY OF ZURICH | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 55d | Pending | Jun 09, 2023 |
| 18320173 | NOVEL METHODS | Intra-Cellular Therapies, Inc. | CHONG, YONG SOO | 1623 | DP | Final Rejection | — | Pending | May 18, 2023 |
| 18304987 | USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA | Fudan University | MEJIAS, SAMANTHA LEE | 1618 | §102§103§112 | Non-Final OA | 88d overdue | Pending | Apr 21, 2023 |
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | 34d | Pending | Apr 10, 2023 |
| 18029518 | Prebiotic Oral Care Compositions and Methods | UNIVERSITEIT GENT | LIU, TRACY | 1614 | §103 | Non-Final OA | 15d | Pending | Mar 30, 2023 |
| 18042103 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 17, 2023 |
| 18040618 | PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF | Aeromics, Inc. | ARNOLD, ERNST V | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007018 | NOVEL USES | Intra-Cellular Therapies, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Non-Final OA | 60d overdue | Pending | Jan 26, 2023 |
| 18152110 | SYSTEMS AND METHODS FOR WRITING, READING, AND CONTROLLING DATA STORED IN A POLYMER | Iridia, Inc. | WOOLWINE, SAMUEL C | 1681 | §102§112 | Non-Final OA | — | Pending | Jan 09, 2023 |
| 18066883 | METHODS OF TREATMENT WITH S1P RECEPTOR MODULATORS | Priothera Limited | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Final Rejection | 60d overdue | Pending | Dec 15, 2022 |
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | Genequantum Healthcare (Suzhou) Co., Ltd. | NGUYEN, TAM M | 1771 | §103 | Final Rejection | 25d overdue | Pending | Dec 14, 2022 |
| 17928381 | STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY | Yale University | KATAKAM, SUDHAKAR | 1658 | §112 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 17996276 | USE OF AN ORPHAN MOTIF TO INCREASE EXPRESSION OF A HETEROLOGOUS TRANSGENE | Friedrich Miescher Institute For Biomedical Research | HAMMELL, NEIL P | 1681 | §102DP | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17995220 | THE USE OF DIFFUSION ENHANCING COMPOUNDS FOR TREATMENT OF VIRAL AND BACTERIAL INDUCED RESPIRATORY DISEASE | Diffusion Pharmaceuticals LLC | THOMAS, TIMOTHY P | 1614 | §103 | Non-Final OA | 45d overdue | Pending | Sep 30, 2022 |
| 17758540 | RSPO1 PROTEINS AND THEIR USE | UNIVERSITE COTE D'AZUR | REYNOLDS, FRED H | 1658 | §102DP | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17758352 | COMPOSITIONS HAVING THIOREDOXIN ACTIVITY AND RELATED METHODS | Orpro Therapeutics, Inc. | KOMATSU, LI N | 1658 | DP | Final Rejection | — | Pending | Jul 01, 2022 |
| 17831796 | Oral Care Products and Methods | BASF Corporation | ARNOLD, ERNST V | 1613 | §103 | Final Rejection | 58d overdue | Pending | Jun 03, 2022 |
| 17751512 | SUSPENSION COMPRISING A PROTEIN PARTICLE SUSPENDED IN A NON-AQUEOUS VEHICLE | Novaliq GmbH | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 23, 2022 |
| 17350427 | SEMIFLUORINATED COMPOUNDS | Novaliq GmbH | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 25d overdue | Pending | Jun 17, 2021 |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | Alfasigma S.p.A. | PECKHAM, RICHARD GRANT | 1627 | §103DP | Final Rejection | 26d | Pending | Jun 08, 2021 |
| 17263440 | AGENT FOR INHIBITING RECURRENCE OF HEMATOLOGICAL MALIGNANCY IN PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION | Priothera Limited | KUCHARCZK, JED A | 1623 | §103 | Non-Final OA | — | Pending | Jan 26, 2021 |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Intra-Cellular Therapies, Inc. | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Dec 18, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial